Michelle Chamblee

Nov 13, 2024 | biorxiv.org | Pei Li |Julia Faraone |Michelle Chamblee |Yajie Liu

AbstractSARS-CoV-2 continues to evolve, producing new variants that drive global COVID-19 surges. XEC, a recombinant of KS.1.1 and KP.3.3, contains T22N and F59S mutations in the spike protein's N-terminal domain (NTD). The T22N mutation, similar to the DelS31 mutation in KP.3.1.1, introduces a potential N-linked glycosylation site in XEC.

Nov 6, 2024 | digitalcommons.library.tmc.edu | Pei Li |Julia Faraone |Michelle Chamblee |Yi-Min Zheng

AbstractWe investigate JN.1-derived subvariants SLip, FLiRT, and KP.2 for neutralization by antibodies in vaccinated individuals, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients, or class III monoclonal antibody S309. Compared to JN.1, SLip, KP.2, and especially FLiRT exhibit increased resistance to bivalent-vaccinated and BA.2.86/JN.1-wave convalescent human sera.

Sep 5, 2024 | biorxiv.org | Pei Li |Julia Faraone |Michelle Chamblee |Yajie Liu

AbstractDuring the summer of 2024, COVID-19 cases surged globally, driven by variants derived from JN.1 subvariants of SARS-CoV-2 that feature new mutations, particularly in the N-terminal domain (NTD) of the spike protein.

May 21, 2024 | biorxiv.org | Pei Li |Julia Faraone |Yi-Min Zheng |Michelle Chamblee

AbstractSARS-CoV-2 variants derived from the immune evasive JN.1 are on the rise worldwide. Here, we investigated JN.1-derived subvariants SLip, FLiRT, and KP.2 for their ability to be neutralized by antibodies in bivalent-vaccinated human sera, XBB.1.5 monovalent-vaccinated hamster sera, sera from people infected during the BA.2.86/JN.1 wave, and class III monoclonal antibody (Mab) S309.